Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
UBS
Cipla
Queensland Health
Federal Trade Commission
McKesson
Farmers Insurance
Harvard Business School
Citi

Generated: October 19, 2018

DrugPatentWatch Database Preview

Gd Searle Company Profile

« Back to Dashboard

What is the competitive landscape for GD SEARLE, and what generic alternatives to GD SEARLE drugs are available?

GD SEARLE has forty-six approved drugs.

There are seven US patents protecting GD SEARLE drugs.

Summary for Gd Searle
US Patents:7
Tradenames:41
Ingredients:29
NDAs:46

Drugs and US Patents for Gd Searle

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc CALAN verapamil hydrochloride INJECTABLE;INJECTION 019038-001 Mar 30, 1984 DISCN No No ➤ Sign Up ➤ Sign Up
Gd Searle Llc PRO-BANTHINE propantheline bromide INJECTABLE;INJECTION 008843-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Gd Searle Llc AMINOPHYLLIN aminophylline INJECTABLE;INJECTION 087621-001 May 24, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Gd Searle Llc POTASSIUM CHLORIDE potassium chloride INJECTABLE;INJECTION 086219-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up
Gd Searle Llc AMINOPHYLLIN aminophylline TABLET;ORAL 002386-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Gd Searle Llc DEMULEN 1/50-28 ethinyl estradiol; ethynodiol diacetate TABLET;ORAL-28 016936-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Gd Searle

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 4,612,008 ➤ Sign Up
Gd Searle Llc CU-7 copper INTRAUTERINE DEVICE;INTRAUTERINE 017408-001 Approved Prior to Jan 1, 1982 4,040,417 ➤ Sign Up
Gd Searle Llc CYTOTEC misoprostol TABLET;ORAL 019268-001 Dec 27, 1988 4,459,310 ➤ Sign Up
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996 6,096,339 ➤ Sign Up
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 5,466,823*PED ➤ Sign Up
Gd Searle Llc CYTOTEC misoprostol TABLET;ORAL 019268-001 Dec 27, 1988 4,060,691 ➤ Sign Up
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 4,559,332*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GD SEARLE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 2008-11-28
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2006-09-27
➤ Subscribe Capsules 50 mg ➤ Subscribe 2008-03-21
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 2009-06-29

Supplementary Protection Certificates for Gd Searle Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB03/022 United Kingdom ➤ Sign Up PRODUCT NAME: VALDECOXIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/244/001-024 20030327; UK EU/1/02/239/001-024 20030327; UK EU/1/02/242/001-024 20030327
12/008 Ireland ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1135139/01 Switzerland ➤ Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C0025 Belgium ➤ Sign Up PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
04C/008 Belgium ➤ Sign Up PRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
C/GB02/037 United Kingdom ➤ Sign Up PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C/GB12/028 United Kingdom ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
UBS
Healthtrust
Federal Trade Commission
Cipla
Cerilliant
Chinese Patent Office
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.